Pfizer Oncology Data Presentations at the 2015 ASCO Annual Meeting*

The embargo on all data lifts on Wednesday, May 13, 2015, at 4:00 p.m. CDT

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, multiple abstracts will be presented highlighting clinical progress for 11 Pfizer Oncology assets, including marketed products and investigational compounds. The presentations span multiple tumor types, including breast cancer, renal cell carcinoma, non-Hodgkin’s lymphoma (NHL), chronic myeloid leukemia (CML) and ALK+ or ROS1+ non-small cell lung cancer (NSCLC):

**Breast Cancer Presentations**

**Palbociclib:**

(Abstract #570) Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18). Slamon DJ. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #58.

(Abstract #571) Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial. Crown J. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #59.

(Abstract #572) The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. Finn RS. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #60.

(Abstract #575) Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. Finn RS. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #63.

(Abstract #6586) Breast cancer progression and workplace productivity. Yin W. Monday, June 1. Session Type: Poster. Display Time: 1:15 – 4:45 p.m. CDT. Display Location: S Hall A; Poster Board: #143.

**Lung Cancer Presentations**

**Crizotinib:**

(Abstract #8101) Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). Felip E. Monday, June 1. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #426.

* The underline denotes the lead author of each abstract.
Hematology Presentations

Bosutinib:

(Abstract #7068) Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure. Gambacorti-Passerini C. Sunday, May 31. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #57.

(Abstract #7076) Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure. Lipton JH. Sunday, May 31. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #65.

Gastrointestinal/Genitourinary Presentations

Axitinib:

(Abstract #4545) Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. Rini BI. Monday, June 1. Session Type: Poster. Display Time: 1:15 – 4:45 p.m. CDT. Display Location: S Hall A; Poster Board: #218.

RCC Pan-Asset:

(Abstract #4551) Early tumor shrinkage (eTS) as a predictive and prognostic factor in metastatic renal cell carcinoma (mRCC). Gruenwald V. Monday, June 1. Session Type: Poster. Display Time: 1:15 – 4:45 p.m. CDT. Display Location: S Hall A; Poster Board: #224.

Early Pipeline and Immunotherapy Assets

PF-05082566 (4-1BB mAb inhibitor):


PF-06463922 (ALK-ROS1 inhibitor):

(Abstract #8018) Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. Shaw AT. Monday, June 1. Session Type: Poster Discussion. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #340. Discussion Time: 3:00 – 4:15 p.m. CDT. Discussion Location: E Hall D2.

(Abstract #TPS2620) Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. Bauer TM. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #326b.
PF-06647263: (EFNA4 ADC):

(Abstract #2520) First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. Hong DS. Saturday, May 30. Session Type: Poster Discussion. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #236. Discussion Time: 1:15 – 2:30 p.m. CDT. Discussion Location: S406.

PF-05212384 (PI3K/mTOR inhibitor):

(Abstract #2590) Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents. Wainberg ZA. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #306.

PF-03084014 (Gamma Secretase inhibitor):

(Abstract #1068) Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC). Curigliano G. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #182.

PF-06263507 (5T4 ADC):

(Abstract #TPS2603) First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors. Shapiro G. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #318a.

Biosimilars

PF-05280014 (biosimilar to trastuzumab):

(Abstract #618) Development of PF-05280014, a potential biosimilar to trastuzumab. Jacobs IA. Saturday, May 30. Session Type: Poster. Display Time: 8:00 – 11:30 a.m. CDT. Display Location: S Hall A; Poster Board: #108.

###